Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance
Journal of Hepatocellular Carcinoma · 2023-02 · Volume 10 · 267-279
DOI: 10.2147/jhc.s399874 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepatocellular Carcinoma, 2023-02. Verfasst von Xinhua Zou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tumor Interventional Therapy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjin…. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Tumor Interventional Therapy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing City, People's Republic of China.
Zitieren
APA
Zou, X., Xu, Q., You, R., & Yin, G. (2023). Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance. Journal of Hepatocellular Carcinoma, Volume 10, 267-279. https://doi.org/10.2147/jhc.s399874
Vancouver
Zou X, Xu Q, You R, Yin G. Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance. Journal of Hepatocellular Carcinoma. 2023;Volume 10:267-279. doi:10.2147/jhc.s399874
BibTeX
@article{Zou2023,
author = {Zou, Xinhua and Xu, Qingyu and You, Ran and Yin, Guowen},
title = {Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance},
journal = {Journal of Hepatocellular Carcinoma},
year = {2023},
volume = {Volume 10},
pages = {267--279},
doi = {10.2147/jhc.s399874}
}
EUVIMED